Anticoagulant therapy does not extend survival in people with PAH, according to a French study involving the blood thinners.
Death rates and disability in newborn PAH have declined globally since 1990, but inequalities remain, according to a 30-year ...
The term "October slide" refers to a trend in which many in the chronic illness community face health setbacks, writes ...
Researchers developed PVC, a measure that estimates the reduced function of the pulmonary arteries in pediatric PAH patients, ...
Experimental treatment ALG-801 was shown to be more effective than approved PAH therapies at reducing signs of disease in an ...
The strategy begins with medications, followed by balloon pulmonary angioplasty, and pulmonary endarterectomy surgery, a ...
Long-term treatment with Tyvaso DPI is safe and effective in adults with PAH who were previously on Tyvaso, according to ...
Worldwide, pulmonary arterial hypertension affects more than 2 of every 100,000 women and girls of childbearing age, a new study shows.
Gossamer Bio is moving toward acquiring Respira Therapeutics and its lead treatment candidate, RT234, an inhaled therapy being developed for the on-demand treatment of pulmonary hypertension (PH). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback